- 関
- Pharmaceuticals and Medical Devices Agency
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2016/06/04 21:38:59」(JST)
[Wiki ja表示]
English Journal
- Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns.
- Miyamura K1.
- International journal of hematology.Int J Hematol.2016 Feb;103(2):155-64. doi: 10.1007/s12185-015-1930-x. Epub 2016 Jan 12.
- Acute graft-versus-host disease (aGVHD) is a major obstacle following allogeneic hematopoietic stem cell transplantation. Steroid is the standard treatment for aGVHD grade II-IV; however, nearly half of patients do not respond to the therapy. Many drugs have been proposed, but no standard therapy ha
- PMID 26759322
- Biocompatibility of common polyimides with human endothelial cells for a cardiovascular microsensor.
- Starr P1,2, Agrawal CM2, Bailey S1,2.
- Journal of biomedical materials research. Part A.J Biomed Mater Res A.2016 Feb;104(2):406-12. doi: 10.1002/jbm.a.35578. Epub 2015 Oct 15.
- The cardiovasculature is an emerging niche for polyimide microdevices, yet the biocompatibility of polyimides with human endothelial cells has not been reported in the literature. In this study, we have evaluated an experimental polyimide-based pressure sensor for biological safety to determine its
- PMID 26418753
- Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
- Tazawa Y1.
- Breast cancer (Tokyo, Japan).Breast Cancer.2016 Jan;23(1):19-23. doi: 10.1007/s12282-015-0586-y. Epub 2015 Jan 22.
- BACKGROUND: On July 1st, 2013, the Ministry of Health, Labor and Welfare (MHLW) issued an official notification regarding the co-development of companion diagnostics (CDx) with a drug which requires any exclusive diagnostic test or medical device to predict efficacy or adverse reactions to the drug.
- PMID 25605056
Japanese Journal
- さらなる疑問を解決! PMDA使いこなし術(10)情報を使いやすく加工しよう!
- 中川 雅生,紀平 哲也
- Pediatric Cardiology and Cardiac Surgery 29(3), 109-117, 2013
- わが国の医療保険制度(国民皆保険制度)は世界に誇れる優れたものである.しかし,この保険制度において,小児への適応がない医薬品は適正な医療とみなされず,保険診療において返戻の対象となる可能性がある.実際,この11 年間に薬事法上の承認を受けた医薬品のうち小児適応があるものは20.8%に過ぎず,多くの医薬品が小児には適応がないのが現状である.原則として薬事法上小児適応を有する医薬品が保険適用とされるが …
- NAID 130003380024
- Molecular Imaging-based Early-Phase and Exploratory Clinical Research
- 渡辺 恭良
- YAKUGAKU ZASSHI 133(2), 187-195, 2013
- … In addition, the results of the first cassette-dose and micro-dose clinical trials approved by Pharmaceuticals and Medical Devices Agency (PMDA) (New Energy and Industrial Technology Development Organization (NEDO) project represented by Prof. Yuichi Sugiyama) are described. …
- NAID 130003361902
Related Links
- 医薬品副作用被害救済や稀少病認定薬の研究振興調査などの業務案内。
- WEB申請について WEB申請とは、 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律等の定めにより、PMDAが提出先となって いる医療機器に関する申請・届出類の作成・提出・ 進捗確認までをWEB ...
Related Pictures
★リンクテーブル★
[★]
- 医薬品医療機器総合機構(PMDA)が医療者から収集する副作用・感染症・不具合等の報告に含まれないのはどれか。
[正答]
※国試ナビ4※ [114B014]←[国試_114]→[114B016]
[★]
[★]
- 同
- 原発性心筋疾患
- 同
- 原発性心筋疾患